Ipca Laboratories News and Updates

Name: Latest research reports of Ipca Laboratories Ltd. authored by Prabhudas Lilladhar and published by - Trendlyne research reports.
Item: Ipca Laboratories Ltd.
Rating: 5
Author: Prabhudas Lilladhar

Keep track of all breaking news on Ipca Laboratories from all sources in a single place.

Ipca Laboratories Ltd.

17 Mar 2026, 10:33AM

1543.60

-1.39%

Ipca Labs rallies 4%, stock hits 52-week high; analysts see more upside

Business Standard

Ipca Labs hit a 52-week high of 1,624 on the BSE in Tuesday's intra-day trade amid heavy volumes and was seen inching towards its record high of 1,757.55 touched on January 3, 2025.

Ipca Laboratories Ltd. has an average target of 1773.33 from 3 brokers.

Ipca Laboratories Ltd.

06 Mar 2026

1543.60

-1.39%

Ipca Laboratories (IPCA IN) Management Meet Update Steady growth visibility BUY

Buy: Ipca Laboratories Ltd.

Target

Prabhudas Lilladhar

We interacted with the management of IPCA Laboratories (IPCA) to assess its medium-term growth trajectory. The company is prioritizing disciplined execution over aggressive diversification, with a clear focus on strengthening its core businesses while building growth levers. Domestic formulations and branded generics which now contribute 45% of revenues and ~70% of EBITDA, continued to outperform market and grow at healthy levels. We expect IPCA to deliver revenue growth ex Unichem at +11% over FY26-28E with normalization in export generic and API business. This will aid operating...

Ipca Laboratories Ltd. has an average target of 1773.33 from 3 brokers.

Ipca Laboratories Ltd.

18 Feb 2026, 05:50PM

1543.60

-1.39%

Broker's Call: Ipca Laboratories (Buy)

Business Line

PL Capital

Ipca Laboratories Ltd. has an average target of 1773.33 from 3 brokers.

Ipca Laboratories Ltd.

17 Feb 2026

1543.60

-1.39%

Ipca Laboratories (IPCA IN) Q3FY26 Result Update Margin surprise BUY

Buy: Ipca Laboratories Ltd.

Recommendation Target

Prabhudas Lilladhar

Ipca reported strong EBITDA of Rs5.3bn (up 19% YoY) which was 10% above our estimates. Company has witnessed 400bps GMs expansion ex Unichme for 9MFY26 which should sustain given product mix and softer raw material prices. Export API business witnessed recovery in 9MFY26 with 26% YoY growth. Domestic formulation business, which now contributes 40% of revenues and ~55% of EBITDA, continued to outperform and grow at healthy levels. We believe 1) recovery in API segment 2) higher margins ex Unichem 3) steady...

Prabhudas Lilladhar increased Buy price target of Ipca Laboratories Ltd. to 1800.0 on 06 Mar, 2026.

Ipca Laboratories Ltd.

17 Feb 2026

1543.60

-1.39%